Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.43 -0.00 (-0.03%)
Streaming Delayed Price Updated: 10:08 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. ↗
 
Via Benzinga
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
The Analyst Landscape: 4 Takes On Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
News headline image
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
News headline image
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps ↗
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. 
Via InvestorPlace
Topics Bankruptcy
News headline image
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease ↗
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease. 
Via Benzinga
News headline image
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark ↗
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.